Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LFWD NASDAQ:QNRX NASDAQ:SINT NASDAQ:VBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLFWDLifeward$7.05$6.81$4.14▼$15.36$10.77M0.326,973 shs42,471 shsQNRXQuoin Pharmaceuticals$4.81+0.8%$6.42$4.59▼$41.80$9.58M1.6127,214 shs28,783 shsSINTSintx Technologies$2.39$2.50$1.99▼$6.78$10.32M0.6141,526 shs65,399 shsVBIOValion Bio, Inc. Common Stock$0.85$1.01$0.72▼$5.60$2.73M1.86323,398 shs57,812 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLFWDLifeward0.00%+7.14%-4.47%+40.72%-53.37%QNRXQuoin Pharmaceuticals0.00%-13.02%-15.61%-44.97%-45.96%SINTSintx Technologies0.00%+7.17%-3.24%-19.53%-11.15%VBIOValion Bio, Inc. Common Stock0.00%-0.85%-35.91%+12.14%-79.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLFWDLifeward$7.05$6.81$4.14▼$15.36$10.77M0.326,973 shs42,471 shsQNRXQuoin Pharmaceuticals$4.81+0.8%$6.42$4.59▼$41.80$9.58M1.6127,214 shs28,783 shsSINTSintx Technologies$2.39$2.50$1.99▼$6.78$10.32M0.6141,526 shs65,399 shsVBIOValion Bio, Inc. Common Stock$0.85$1.01$0.72▼$5.60$2.73M1.86323,398 shs57,812 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLFWDLifeward0.00%+7.14%-4.47%+40.72%-53.37%QNRXQuoin Pharmaceuticals0.00%-13.02%-15.61%-44.97%-45.96%SINTSintx Technologies0.00%+7.17%-3.24%-19.53%-11.15%VBIOValion Bio, Inc. Common Stock0.00%-0.85%-35.91%+12.14%-79.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLFWDLifeward 2.00Hold$10.0041.84% UpsideQNRXQuoin Pharmaceuticals 1.00SellN/AN/ASINTSintx Technologies 2.33Hold$11.00360.25% UpsideVBIOValion Bio, Inc. Common Stock 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest VBIO, QNRX, LFWD, and SINT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026SINTSintx Technologies HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.004/22/2026QNRXQuoin Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026LFWDLifeward Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026SINTSintx Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026VBIOValion Bio, Inc. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/13/2026SINTSintx Technologies HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.004/8/2026SINTSintx Technologies Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $12.003/19/2026LFWDLifeward HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLFWDLifeward$22.03M0.49N/AN/A$4.12 per share1.71QNRXQuoin PharmaceuticalsN/AN/AN/AN/A$4.37 per shareN/ASINTSintx Technologies$1.02M10.12N/AN/A$0.21 per share11.38VBIOValion Bio, Inc. Common Stock$780K3.50N/AN/A$3.46 per share0.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLFWDLifeward-$19.91M-$19.66N/AN/AN/A-123.66%-243.14%-97.39%8/13/2026 (Estimated)QNRXQuoin Pharmaceuticals-$15.81M-$29.56N/AN/AN/AN/A-489.85%-221.29%8/6/2026 (Estimated)SINTSintx Technologies-$10.36M-$5.07N/AN/AN/A-1,058.60%-366.49%-115.04%8/13/2026 (Estimated)VBIOValion Bio, Inc. Common Stock-$8.88M-$6.68N/AN/AN/AN/A-138.10%-63.67%N/ALatest VBIO, QNRX, LFWD, and SINT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026LFWDLifeward-$1.18-$6.70-$5.52-$6.70$5.78 million$3.92 million5/15/2026Q1 2026SINTSintx Technologies-$0.66-$0.70-$0.04-$0.70$0.30 million$0.38 million5/14/2026Q1 2026VBIOValion Bio, Inc. Common StockN/A-$2.23N/A-$2.23N/AN/A5/7/2026Q1 2026QNRXQuoin Pharmaceuticals-$2.17-$1.77+$0.40-$1.77N/AN/A3/30/2026Q4 2025VBIOValion Bio, Inc. Common Stock-$408.00-$1.0310+$406.9690-$1.35$0.46 millionN/A3/27/2026Q4 2025QNRXQuoin Pharmaceuticals-$6.42-$14.80-$8.38-$1.74N/AN/A3/19/2026Q4 2025LFWDLifeward-$0.07-$3.60-$3.53-$3.60$7.87 million$5.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLFWDLifewardN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ASINTSintx TechnologiesN/AN/AN/AN/AN/AVBIOValion Bio, Inc. Common StockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLFWDLifeward1.162.400.84QNRXQuoin PharmaceuticalsN/A2.872.87SINTSintx TechnologiesN/A1.041.29VBIOValion Bio, Inc. Common Stock0.623.313.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLFWDLifeward26.76%QNRXQuoin Pharmaceuticals8.63%SINTSintx Technologies18.38%VBIOValion Bio, Inc. Common Stock4.25%Insider OwnershipCompanyInsider OwnershipLFWDLifeward1.50%QNRXQuoin Pharmaceuticals13.46%SINTSintx Technologies4.08%VBIOValion Bio, Inc. Common Stock14.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLFWDLifeward601.53 million1.51 millionOptionableQNRXQuoin Pharmaceuticals42.01 million1.74 millionNot OptionableSINTSintx Technologies404.32 million4.14 millionNot OptionableVBIOValion Bio, Inc. Common Stock103.20 million2.74 millionNot OptionableVBIO, QNRX, LFWD, and SINT HeadlinesRecent News About These CompaniesVALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROMEMay 19, 2026 | prnewswire.comValion Bio, Inc.: Valion Bio Reports First Quarter 2026 Financial ResultsMay 15, 2026 | finanznachrichten.deValion Bio, Inc. Common Stock Q1 Earnings Call HighlightsMay 15, 2026 | americanbankingnews.comValion Bio outlines end-2026 Entolimod GMP validation target as NIAID funds GI-ARS BLA-enabling workMay 14, 2026 | seekingalpha.comValion Bio Inc. (VBIO) Q1 2026 Earnings Call Prepared Remarks TranscriptMay 14, 2026 | seekingalpha.comValion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ PlatformMay 14, 2026 | prnewswire.comVALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTSMay 14, 2026 | prnewswire.comValion Bio to Report First Quarter 2026 Financial Results on May 14, 2026May 11, 2026 | prnewswire.comValion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™May 6, 2026 | prnewswire.comVALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSIONMay 5, 2026 | prnewswire.comTivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple ...April 23, 2026 | finance.yahoo.comTivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream ModelApril 23, 2026 | prnewswire.comSheryle Bolton Purchases 10,000 Shares of Tivic Health Systems (NASDAQ:TIVC) StockApril 21, 2026 | insidertrades.comTivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7thApril 15, 2026 | prnewswire.comTivic Health Systems, Inc.April 3, 2026 | edition.cnn.comTivic Health Systems (NASDAQ:TIVC) Director Christina Rizopoulos Valauri Acquires 19,000 SharesApril 3, 2026 | insidertrades.comTivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of EntolimodMarch 31, 2026 | accessnewswire.comAHead to Head Analysis: Tivic Health Systems (NASDAQ:TIVC) versus American Well (NYSE:AMWL)March 29, 2026 | defenseworld.netDTivic Health Systems: Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual ConferenceMarch 27, 2026 | finanznachrichten.deTivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual ConferenceMarch 27, 2026 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeVBIO, QNRX, LFWD, and SINT Company DescriptionsLifeward NASDAQ:LFWD$7.05 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$6.60 -0.46 (-6.45%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.Quoin Pharmaceuticals NASDAQ:QNRX$4.81 +0.04 (+0.84%) Closing price 05/22/2026 03:58 PM EasternExtended Trading$4.75 -0.06 (-1.23%) As of 05/22/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.Sintx Technologies NASDAQ:SINT$2.39 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.24 -0.15 (-6.28%) As of 05/22/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.Valion Bio, Inc. Common Stock NASDAQ:VBIO$0.85 0.00 (0.00%) As of 05/22/2026 04:00 PM EasternTivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
